Brief: Rigel Enters Exclusive Global Licensing Agreement For Veppanu
12/05/2026 12:01
May 12 (Reuters) - Rigel Pharmaceuticals Inc RIGL.O: RIGEL ENTERS EXCLUSIVE GLOBAL LICENSING AGREEMENT FOR VEPPANU™ (VEPDEGESTRANT), AN ORAL PROTAC, FOR THE TREATMENT OF 2L+ ER+/HER2-, ESR1M ADVANCED OR METASTATIC BREAST CANCER RIGEL PHARMACEUTICALS INC - TO CONTRIBUTE UP TO $40 MILLION FOR DEVELOPMENT OVER NEXT FOUR YEARS Source text: ID:nPn1CZfwga Further company coverage: RIGL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rigel Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rigel Pharmaceuticals Q2 revenue rises on strong product demand
Brief: Rigel Pharmaceuticals - Appoints Alison L. Hannah As Executive Vice President And Chief Medical Officer Effective July 1, 2026 - SEC Filing
Brief: Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)